tbuckley/cabot-search huggingface dataset:
Dexamethasone-loaded ROS-responsive poly(thioketal) nanoparticles suppress inflammation and oxidative stress of acute lung injury
Authors: Zihe Zhai, Wei Ouyang, Yuejun Yao, Yuqi Zhang, Haolan Zhang, Feng Xu, Changyou Gao
Journal: Bioactive Materials (2022)

Acute lung injury (ALI) is associated with excessive inflammatory response, leading to acute respiratory distress syndrome (ARDS) without timely treatment. A fewer effective drugs are available currently to treat the ALI/ARDS. Herein, a therapeutic nanoplatform with reactive oxygen species (ROS)-responsiveness was developed for the regulation of inflammation. Dexamethasone acetate (Dex) was encapsulated into poly(thioketal) polymers to form polymeric nanoparticles (NPs) (PTKNPs@Dex). The NPs were composed of poly(1,4-phenyleneacetonedimethylene thioketal) (PPADT) and polythioketal urethane (PTKU), in which the thioketal bonds could be cleaved by the high level of ROS at the ALI site. The PTKNPs@Dex could accumulate in the pulmonary inflammatory sites and release the encapsulated payloads rapidly, leading to the decreased ROS level, less generation of pro-inflammatory cytokines, and reduced lung injury and mortality of mice. RNA sequencing (RNA-seq) analysis showed that the therapeutic efficacy of the NPs was associated with the modulation of many immune and inflammation-linked pathways. These findings provide a newly developed nanoplatform for the efficient treatment of ALI/ARDS.
Proceedings of the Thoracic Society
Journal: Thorax (1979)

Oesophageal injury from therapeutic agents has been reported with increasing frequency and with an increasingly wide range of drugs since 1970.We report a recent case of oesophagitis due to emepronium bromide (Cetiprin) at the Queen Elizabeth Hospital, Birmingham, and review all the reported instances of oesophageal damage caused by this and other drugs.A 15-year-old school girl developed severe pain and difficulty on swallowing two months after starting emepronium for mild urinary incontinence.A barium swallow was normal but endoscopy showed severe ulcerative oesophagitis at the level of the aortic arch.There was no other oesophageal abnormality.Special radiological and manometric studies established a con- nection between the drug and the oesophageal lesion, and complete healing occurred on withdrawal of the drug.Forty-one other cases of oesophageal damage due to eight different drugs have been reported, with nine drug-related deaths.The clinical and pathological features of these are reviewed in the hope of avoiding further instances of yet another iatrogenic disease.
CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Authors: Wen-Hsuan Wu, Yi-Ting Tsai, I-Wen Huang, Chia-Hua Cheng, Chun-Wei Hsu, Xuan Cui, Joseph Ryu, Peter M.J. Quinn, Salvatore Marco Caruso, Chyuang-Sheng Lin, Stephen H. Tsang
Journal: Molecular Therapy (2022)

Mutations in rhodopsin (RHO) are the most common causes of autosomal dominant retinitis pigmentosa (adRP), accounting for 20% to 30% of all cases worldwide. However, the high degree of genetic heterogeneity makes development of effective therapies cumbersome. To provide a universal solution to RHO-related adRP, we devised a CRISPR-based, mutation-independent gene ablation and replacement (AR) compound therapy carried by a dual AAV2/8 system. Moreover, we developed a novel hRHO
Chronic hepatitis.
Authors: S Sherlock
Journal: Gut (1974)

Progress report Chronic hepatitisChronic hepatitis is defined as a chronic inflammatory reaction in the liver as shown by liver function tests and histology and continuing without improvement for at least six months.1 Morphologically, the two varieties of chronic persistent and chronic aggressive hepatitis (the latter better called active chronic hepatitis) can be described as 'chronic active liver disease'2.The aetiology of these conditions is only partly recognized.All may be associated with the presence of hepatitis B antigen in the serum and are then considered to represent sequelae of acute B virus hepatitis.The type A virus (or other agents) may also be responsible.Some are associated with marked disturbances in immunity and the term 'lupoid' is applied to this group.Identical clinical, functional, and morphological features may be found associated with some drug reactions, for instance, to oxyphenisatin in laxatives, methyldopa, and isonicotinic acid hydrazide (INAH).Wilson's disease can also present as active chronic liver disease ( 101) as can alpha, antitrypsin deficiency (see fig).Copper 1 CHRONIC ACTIVE Drugs NECROSIS HEPATITIS HBAg P immunity oc antitrypsin P Mechanism CIRRHOSIS Fig Aetiological factors concerned in active chronic liver disease.Chronic persistent hepatitis is characterized histologically by mainly portal inflammatory infiltration, preserved lobular architecture, and slight to absent fibrosis.Piecemeal hepatocellular necrosis is not conspicuous.Chronic active hepatitis (formerly called aggressive hepatitis) is marked by on July 15, 2023 by guest.
Bacterial Shock
Authors: Jack A. Barnett
Journal: JAMA (1969)

As a cause of clinical shock, sepsis is surpassed in frequency only by hemorrhage and myocardial infarction. The most common offending organisms are gram-negative bacteria, although septic shock may occasionally occur after infection with fungi, rickettsiae, viruses, and gram-positive bacteria. Infections with gram-negative bacilli are increasing in frequency and at present constitute the most commonly encountered life-threatening infections in patients in general hospitals. The mortality in large accumulated series of patients with gram-negative bacteremia approximates 40%. In patients in whom shock develops as a consequence of the bacteremia, the death rate ranges from 50% to 80%. <h3>Mechanism</h3> The pathophysiology of bacterial shock is incompletely understood. It is believed, however, that endotoxin, a complex lipopolysaccharide common to the cell wall of all gram-negative bacteria, plays a major role in initiating the hemodynamic events.<sup>1</sup>Most experimental evidence supports the view that endotoxin effects a redistribution of blood within the vascular bed
Susceptibility of N Gonorrhoeae to Antibiotics: Study of 200 Consecutive Strains Isolated in Winnipeg in 1962
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The UK is an international outlier in its approach to covid in children
Authors: Simon Williams, Susan Michie, Christina Pagel, Adam Squires
Journal: BMJ (2022)

Recent declines in the overall rates of covid-19 in the UK have masked the rapid and steep rise in cases among children.As of 26 January 2022, Office for National Statistics data suggest that nearly 12% of children in primary school and below (ages 2 to 11), and 6.5% of children in secondary school (ages 11 to 16), tested positive for covid-19.
2013 ACCF/AHA Guideline for the Management of Heart Failure
Authors: Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E. Casey, Mark H. Drazner, Gregg C. Fonarow, Stephen A. Geraci, Tamara Horwich, James L. Januzzi, Maryl R. Johnson, Edward K. Kasper, Wayne C. Levy, Frederick A. Masoudi, Patrick E. McBride, John J.V. McMurray, Judith E. Mitchell, Pamela N. Peterson, Barbara Riegel, Flora Sam, Lynne W. Stevenson, W.H. Wilson Tang, Emily J. Tsai, Bruce L. Wilkoff
Journal: Circulation (2013)
Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.
Authors: I Greer, G Cooke, E Dewar, M Evans, C Forbes, A Mollan, J Scurr, M De Swiet, ( London
Journal: BMJ (1992)

An important (but neglected) part of history taking on admission is inquiry about previous episodes of venous thromboembolism.Patients with previous episodes form a high risk group, with a risk of postoperative deep vein thrombosis of over 50%,2122
SCHOOLS IN THEIR EFFECTS ON THE HEALTH OF GROWING GIRLS.
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Childhood Malignant Tumors
Authors: David H. James
Journal: JAMA (1966)

THE ANTIBIOTIC, dactinomycin, and the alkaloid, vincristine sulfate, have each produced objective tumor regression in children with a variety of malignant neoplasms.<sup>1</sup>The best responses to dactinomycin have occurred in cases of Wilms' tumor and rhabdomyosarcoma, although tumor regression has occasionally been observed in children with lymphoma, neuroblastoma, and other neoplasms. The antitumor spectrum of vincristine sulfate has included lymphomas, Wilms' tumor, rhabdomyosarcoma, neuroblastoma, Ewing's sarcoma, retinoblastoma, and liposarcoma. Dactinomycin acts by binding the guanine moiety of deoxyribonucleic acid and thereby preventing the formation of the enzyme, ribonucleic acid polymerase.<sup>2</sup>As a result, ribonucleic acid and protein synthesis are suppressed and cellular damage occurs. Although the specific mechanism of action of vincristine sulfate is unknown, it prevents cell division by interfering in some way with the formation of organization of the spindle tubules of the mitotic apparatus.<sup>3</sup> Since the limiting toxic effect of dactinomycin therapy is most
Lectures on Obstetric Nursing.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quinidine-digoxin interaction
Authors: Gary R. Matzke, Wayne S. Burkle
Journal: JAMA (1979)

<h3>To the Editor.—</h3> We read the report by Leahey et al (240:533,1978) of a possible interference with serum digoxin concentrations by quinidine. Indeed, we as well as others have made similar observations.<sup>1</sup>However, based on the data presented, we have some reservations regarding the incidence of this interaction. Many of the serum digoxin concentrations reported as steady-state values before quinidine therapy were considerably lower than would have been expected based on the dose of digoxin supposedly being administered. We estimated the steady-state serum digoxin concentrations for hypothetical patients with creatinine clearances of 50, 75, and 100 mL/min to be 1.9, 1.5, and 1.2 ng/mL, respectively.<sup>2</sup>(To make these calculations, we assumed a lean body weight of 70 kg and daily administration of 0.25 mg of digoxin with 80% absorption.) Since these calculated serum digoxin concentration values are considerably higher than many of those reported by the authors, we question
Direct cellular reprogramming enables development of viral T antigen–driven Merkel cell carcinoma in mice
Authors: Monique E. Verhaegen, Paul W. Harms, Julia J. Van Goor, Jacob Arche, Matthew T. Patrick, Dawn Wilbert, Haley Zabawa, Marina Grachtchouk, Chia-Jen Liu, Kevin Hu, Michael C. Kelly, Ping Chen, Thomas L. Saunders, Stephan Weidinger, Li-Jyun Syu, John S. Runge, Johann E. Gudjonsson, Sunny Y. Wong, Isaac Brownell, Marcin Cieslik, Aaron M. Udager, Arul M. Chinnaiyan, Lam C. Tsoi, Andrzej A. Dlugosz
Journal: Journal of Clinical Investigation (2022)

Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer that frequently carries an integrated Merkel cell polyomavirus (MCPyV) genome and expresses viral transforming antigens (TAgs). MCC tumor cells also express signature genes detected in skin-resident, postmitotic Merkel cells, including atonal bHLH transcription factor 1 (ATOH1), which is required for Merkel cell development from epidermal progenitors. We now report the use of in vivo cellular reprogramming, using ATOH1, to drive MCC development from murine epidermis. We generated mice that conditionally expressed MCPyV TAgs and ATOH1 in epidermal cells, yielding microscopic collections of proliferating MCC-like cells arising from hair follicles. Immunostaining of these nascent tumors revealed p53 accumulation and apoptosis, and targeted deletion of transformation related protein 53 (Trp53) led to development of gross skin tumors with classic MCC histology and marker expression. Global transcriptome analysis confirmed the close similarity of mouse and human MCCs, and hierarchical clustering showed conserved upregulation of signature genes. Our data establish that expression of MCPyV TAgs in ATOH1-reprogrammed epidermal cells and their neuroendocrine progeny initiates hair follicle-derived MCC tumorigenesis in adult mice. Moreover, progression to full-blown MCC in this model requires loss of p53, mimicking the functional inhibition of p53 reported in human MCPyV-positive MCCs.
Glutamine, myo-inositol, and brain edema in acute liver failure
Authors: J Cordoba
Journal: Hepatology (1996)

a predictor of subsequent response to interferon-a therapy in Japthe study of Nossbaum et al. 3 ), type 1b HCV was found anese patients with chronic hepatitis C. J Med Virol 1994;44:410more frequently in older patients and was more likely 414.to be associated with acquisition via blood transfusion 7.
Clinical Lecture on Idiopathic Anaemia
Authors: J. M. Finny
Journal: BMJ (1880)

admitted to hospital under my care on March 2nd, 1879.She is a another of five children.History.-She had enjoyed good health, and had led an active life as general in-door servant up to five years ago, when her health became impaired.This ill-health she attributed to the effects of a mental shock produced by the sudden and unexpected news of a rupture of a close family tie.Haemorrhage from the womb was brought on at the time, though as to whether it was profuse was not noted.The menses had quietly and regularly ceased full twelve years before this bleeding.Since 1874, she had never been strong, and, year by year, her weakness and pallor had gradually increased.On admission, her appearance was remarkably anaemic, differing from that of simple anaemia on the one hand, and chlorosis on the other, in
Protein metabolism; influence of growth hormone, anabolic steroids, and nutrition in health and disease. An international symposium, Leyden, 25th-26th June, 1962.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022
Authors: Anne M. Hause, James Baggs, Paige Marquez, Tanya R. Myers, John R. Su, Phillip G. Blanc, Jane A. Gwira Baumblatt, Emily Jane Woo, Julianne Gee, Tom T. Shimabukuro, David K. Shay
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

approximately 82.6 million U.S. residents aged ≥18 years received a COVID-19 vaccine booster dose.*The Food and Drug Administration (FDA) has authorized a booster dose of either the same product administered for the primary series (homologous) or a booster dose that differs from the product administered for the primary series (heterologous).These booster authorizations apply to all three COVID-19 vaccines used in the United States (1-3).† The Advisory Committee on Immunization Practices (ACIP) recommended preferential use of an mRNA COVID-19 vaccine (mRNA-1273 [Moderna] or BNT162b2 [Pfizer-BioNTech]) for a booster, even for persons who received the Ad26.COV2.S (Janssen [Johnson & Johnson]) COVID-19 vaccine for their single-dose primary series.§ To characterize the safety of COVID-19 vaccine boosters among persons aged ≥18 years during September 22, 2021-February 6, 2022, CDC reviewed adverse events and health impact assessments following receipt of a booster that were reported to v-safe, a voluntary smartphone-based safety surveillance system for adverse events after COVID-19 vaccination, and adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), a passive vaccine safety surveillance system managed by CDC and FDA.Among 721,562 v-safe registrants aged ≥18 years who reported receiving a booster, 88.8% received homologous COVID-19 mRNA vaccination.Among registrants who reported a homologous COVID-19 mRNA booster dose, systemic reactions were less frequent following the booster (58.4% [Pfizer-BioNTech] and 64.4% [Moderna], respectively) than were those following dose 2 (66.7% and 78.4%, respectively).The adjusted odds of reporting a systemic reaction were higher following a Moderna COVID-19 vaccine booster, irrespective of the vaccine received * https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic† The FDA has authorized a booster dose of either the same product administered for the primary series (homologous) or a booster dose that differs from the product administered for the primary series (heterologous).These booster authorizations apply to all three COVID-19 vaccines used in the United States: 1) Pfizer-BioNTech COVID-19 vaccine ≥5 months after dose 2 for persons aged ≥12 years, 2) Moderna COVID-19 vaccine ≥5 months after dose 2 for persons aged ≥18 years, and 3) Janssen COVID-19 vaccine ≥2 months after a single dose for persons aged ≥18 years.§ https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19vaccines-us.html
SWEDEN
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal